## **REMARKS**

Applicants respectfully request reconsideration of the present application in view of the foregoing amendments and in view of the reasons that follow.

By the present communication, claims 26, 81, and 83 are amended. By the present communication claims 52-80 and 84 are cancelled without prejudice and may form the basis for one or more timely filed divisional applications, claims 1-25 and 29-51 having been cancelled by previous amendment. After amending the claims as set forth above, claims 26-28 and 81-83 are pending in the application with claims 82 and 83 being withdrawn as being directed to non-elected subject matter. Claims 26-28 and 81 are pending and under examination. A listing of all pending claims is provided with status identifiers.

## I. 35 U.S.C. §112, 1<sup>st</sup> and 2<sup>nd</sup> Paragraph Rejections

Claims 26-28 and 81 stand rejected under 35 U.S.C. §112, 1<sup>st</sup> paragraph, as allegedly failing to comply with the written description requirement and under 35 U.S.C. §112, 2<sup>nd</sup> paragraph as allegedly failing to particularly point out and distinctly claim the subject matter which Applicants regard as the invention. The Examiner indicates that the present application does not sufficiently describe the invention as it relates to ligands for G-protein coupled receptors and further that it is unclear what ligands for a G-protein coupled receptor are compatible with the instant invention. Solely for the purposes of advancing prosecution, Applicants have amended the claims to no longer recite ligands for G-protein coupled receptors. Withdrawal of this ground of rejection is respectfully requested.

## II. 35 U.S.C. §102(b) Rejection

Claims 26-28 and 81 stand rejected under 35 U.S.C. §102(b) as allegedly anticipated by Illig *et al.* (WO 00/47578). In support of the rejection, the Examiner points to Example 197(a) of WO 00/47578 (page 225, lines 4-22). Because none of the pending claims embrace the allegedly anticipatory compound, Applicants respectfully traverse.

Example 197(a) is reproduced below for convenience. As is readily apparent, such a compound is a 6-quinolinyl compound.

In response to a restriction requirement dated January 03, 2011, Applicants elected Group I, claims 26-28 and 81. Applicants further elected a species for search and initial examination, where L is quinolinyl, R is (CH<sub>2</sub>)<sub>4</sub>CH(NH<sub>2</sub>)(COOH), Z is COOH, and m and n are 1. For convenience, claim 26 is recited, in part, below.

A compound represented by C:

$$L_{\bigvee_{n}^{N}\bigvee_{m}^{Z}}$$

(

wherein...

...L is selected from the group consisting of

None of the above groups for L correspond to a 6-quinolinyl compound, including the quinolinyl group elected by Applicants, which is a 2-quinolinyl group. Accordingly, Example 197(a) as cited by the Examiner cannot anticipate the claims. Withdrawal of this ground of rejection is respectfully requested.

## III. Request For Rejoinder

As set forth in the Restriction Requirement of January 3, 2011, the Examiner noted that the process claims may be rejoined to the application upon allowance of a product claim. *See* item number 7. Accordingly, Applicant respectfully requests rejoinder of claims 82 and 83.

\* \* \*

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested. The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date June 15, 2011

FOLEY & LARDNER LLP

Customer Number: 48329

Telephone: (608) 258-4288 Facsimile: (608) 258-4258 By /Jeffrey R. Lomprey/

Jeffrey R. Lomprey Attorney for Applicants Registration No. 55,401